405231-02-9

Upstream product

• 31598-80-8 2,3,5-Tri-O-benzyl-1-O-(p-nitrobenzoyl)-β-D-arabinofuranose 
• 60186-30-3 4,6-difluoro-1H-imidazo[4,5-c]pyridine 
• 405231-22-3 1-[(1-acetyloxy-1-ethoxy)methyl]-4,6-difluoroimidazo[4,5-c]pyridine 
• 405230-85-5 2,6-difluoro-4-nitraminopyridine 
• 1737-93-5 3,5-dichloro-2,4,6-trifluoropyridine 
• 2840-00-8 4-amino-3,5-dichloro-2,6-difluoropyridine 
• 60186-20-1 4-amino-2,6-difluoro-5-nitropyridine 
• 60186-25-6 3,4-diamino-2,6-difluoropyridine 
• 63489-58-7 4-amino-2,6-difluoropyridine 

Downstream Products

• 405231-03-0 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 
• 405231-04-1 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.